The mechanism of cortisol-induced hypertension remains unknown. We investigated a possible role of erythropoietin (EPO) as a mediator of hypertension in healthy male subjects treated with cortisol. In Study 1, blood pressure (BP) and serum EPO concentrations were measured on alternate days in nine subjects treated with 80 mg of cortisol per day for 5 days. In Study 2 the same parameters were measured in eight subjects randomised to cortisol (80 mg/day) or placebo and 10 subjects randomised to cortisol (200 mg/day) or placebo for 5 days. In Study 1, cortisol caused a significant increase in systolic BP (SBP) (115 ؎ 2 vs 126 ؎ 2 mm Hg, control vs day 5, P Ͻ 0.001) and serum EPO
Introduction
Hypertension is a frequent complication of exogenous or endogenous cortisol excess. Changes in cortisol secretion or metabolism have been implicated in a variety of forms of hypertension including Cushing's syndrome, the syndrome of apparent mineralocorticoid excess, liquorice abuse and some subsets of essential hypertension. 1 Despite the importance of cortisol as a mediator of hypertension, the mechanism by which cortisol raises blood pressure remains unknown. We have previously demonstrated that cortisol-induced hypertension is amplified but not dependent on sodium intake 1 and is not prevented by blockade of the mineralocorticoid receptor by spironolactone. 2 The activity of the sympathetic nervous system and renin angiotensin system is suppressed by cortisol and therefore these are unlikely to be mediators of cortisol-induced hypertension. 1, 3, 4 Several observations suggest an important role for altered vascular reactivity in the pathogenesis of cortisol-induced hypertension. Vascular reactivity to phenylephrine and angiotensin is increased in cortisol treated subjects. 1, 3 Cortisol treatment also causes suppression of the nitric oxide system as evidenced by reduced plasma nitrate/nitrite concentrations. 5 In the context of these observations, 6,7 EPO-induced hypertension has also been demonstrated to be due in part to nitric oxide resistance. 8 The aim of the current study was to examine the role of EPO as a possible mediator of cortisolinduced hypertension.
Materials and methods
Twenty-seven healthy male subjects who were nonsmokers with no history of hypertension and no contra-indications to cortisol administration were recruited for these studies. Ethical approval was obtained by the South Eastern Area Health Service Ethics Committee and the Committee for Experimental Procedures in Human Subjects at the University of NSW. All subjects provided written informed consent.
Two studies were performed. Study 1 was an open labelled study in which nine subjects received treatment with cortisol 80 mg per day for 5 days. Subjects were commenced on a fixed sodium diet (150 mmol/day) for 3 days prior to cortisol administration and continued throughout the cortisol treatment and washout period. Subjects were asked to abstain from alcohol and to maintain their caffeine intake of less than two cups per day with no caffeine in the 12 h prior to each measurement. On the second day of the pretreatment phase, on days 1, 3 and 5 of cortisol treatment and 2 days following the cessation of treatment, subjects attended the Clinical Research Unit for blood pressure measurement and blood sampling. Supine blood pressure was measured using a random Hawksley sphygmomanometer after 15 min recumbency. Readings were the mean of three consecutive readings within 6 mm Hg mean arterial pressure of each other. All blood pressure measurements and blood samples were taken at the same time of day in each subject in all of the studies.
Study 2 was a double-blind randomised placebo controlled study. Eight subjects were randomised to 5 days of treatment with cortisol 80 mg per day or placebo. After a 2-week washout period, subjects were crossed over to the alternate treatment. The remaining 10 subjects were randomised to treatment with cortisol 200 mg per day or placebo. After a 2-week washout period they were randomised to the alternate treatment (placebo or cortisol 200 mg per day). The same conditions of sodium, alcohol and caffeine intake as used in Study 1 were applied in each phase of Study 2. In Study 2, blood pressure and blood samples were taken on day 5 of each treatment phase. In each study, both cortisol and placebo were administered in four divided doses per day. Cortisol was administered as oral hydrocortisone (Alphapharm, 20 mg tablets).
All the blood samples were stored at −20°C until assay. Serum EPO concentrations were measured by ELISA using a commercial kit (Predictor ELISA kit, Genzyme Corporation, Cambridge, USA). The interassay coefficient of variation was 7%. Serum cortisol concentrations were measured by radioimmunoassay (Amelex Cortisol RIA, Amersham, UK). Samples from each study were measured in the same assay.
Data are reported as mean ± s.e.m. Data were analysed using the SYSTAT statistical program. Paired data were compared using a paired Student's t-test if parametric or Wilcoxin Sign rank test if non-parametric. Linear regression analysis was used to examine the relationship between changes in blood pressure, EPO concentration and haematocrit in Study 2.
Results

Study 1
The 5-day treatment period with cortisol was associated with a progressive rise in serum cortisol concentration (402 ± 27 to 1001 ± 144 nmol/L control vs treatment day 5, P Ͻ 0.001). Over this time period there was a progressive rise in SBP (115 ± 2 to 126 ± 2 mm Hg, P Ͻ 0.001), serum EPO concentration (14.5 ± 2.7 to 24.3 ± 2.7 mU/mL, P Ͻ 0.001) and a fall in haematocrit (0.434 ± 0.01 to 0.417 ± 0.01, P Ͻ 0.05) (Figure 1) . These values tended back towards pretreatment levels within 2 days of cortisol withdrawal (Figure 1 ). The rise in serum EPO concentration was evident within 24 h of commencing cortisol, however, plasma haematocrit was not significantly reduced until day 3 of cortisol treatment (Figure 1 ).
These changes were seen in the context of the usual metabolic effect expected with cortisol treat- ment as described previously. [1] [2] [3] [4] Thus there was a significant increase in body weight (72.8 ± 4.1 to 73.6 ± 4.1 kg, P = 0.02) and there were significant falls in serum potassium (4.3 ± 0.1 to 4.0 ± 0.1 mmol/L, P = 0.03) and serum albumin (44 ± 1 to 42 ± 1 g/L, P = 0.04). There was a non-significant increase in plasma glucose concentration (5.4 ± 0.2 to 6.8 ± 0.6 mmol/L, P = 0.06).
Study 2
Subjects treated with 80 mg of cortisol experienced a significant rise in supine blood pressure (118 ± 2 vs 113 ± 2 mm Hg, cortisol vs placebo, P Ͻ 0.05). This was accompanied by a non-significant rise in serum EPO concentration (21.3 ± 2.9 vs 14.9 ± 3.1 mU/mL) and fall in haematocrit (0.426 ± 0.01 vs 0.434 ± 0.01). A larger increase in blood pressure was noted in subjects treated with cortisol 200 mg per day (129 ± 3 vs 114 ± 2, cortisol 200 mg vs placebo, P Ͻ 0.001). This was accompanied by a significant increase in serum EPO concentration (25.2 ± 11.9 vs 15.9 ± 3.5 mU/mL, P Ͻ 0.01) and a fall in haematocrit (0.418 ± 0.01 vs 0.434 ± 0.01, P Ͻ 0.05). Plasma cortisol concentrations were significantly increased by treatment with cortisol 80 mg per day (849 ± 57 vs 383 ± 32 nmol/L, P Ͻ 0.01) and 200 mg per day (1968 ± 335 vs 361 ± 29 nmol/L, P Ͻ 0.01).
In subjects treated with 200 mg of cortisol per day the change in systolic blood pressure was positively and significantly correlated to the change in plasma EPO concentration (r 2 = 0.43, P Ͻ 0.05, Figure 2 ). There was no significant relationship between the change in plasma EPO concentration and the fall in haematocrit.
Significant increases in body weight were seen during the 80 mg cortisol treatment (70.4 ± 2.8 to 71.4 ± 2.8 kg, control vs treatment day 5, P Ͻ 0.001) but no significant change during placebo treatment (70.2 ± 3.1 vs 70.4 ± 3.2, not significant). In subjects treated with 200 mg cortisol per day body weight increased significantly (78.1 ± 5.4 to 79.2 ± 5.6 kg, P Ͻ 0.01). There were also significant reductions in serum potassium (4.3 ± 0.1 vs 3.9 ± 0.1 mmol/L, P = 0.01) and serum albumin (45 ± 1 vs 42 ± 1 g/L, P = 0.005). There were no significant changes in these parameters during the placebo phase of the study.
Discussion
These results demonstrate that cortisol-induced hypertension is accompanied by a rise in serum EPO concentrations. The rise in serum EPO concentration occurs within 24 h of cortisol administration and occurs over a similar time frame as the cortisolinduced rise in blood pressure. Both blood pressure and serum EPO concentrations fall towards normal values within 48 h of cortisol withdrawal. In the placebo controlled studies, a significant correlation between the rise in blood pressure induced by doses of cortisol 200 mg per day and the change in serum EPO concentrations was observed. No such relationship was observed in the 80 mg study, however, this may have been due to the lower number of subjects used in this study group.
The mechanisms by which EPO concentrations rise during cortisol administration were not addressed by this study. The fall in haematocrit seen in Study 1 and Study 2 has previously been reported in cortisol treated subjects and is due to expansion of plasma volume which occurs during cortisol treatment. 1 Although plasma volume was not directly measured during these studies, the increase in body weight and the fall in serum albumin observed during each cortisol treatment phase is compatible with the notion that fluid retention and plasma volume expansion did indeed occur during Journal of Human Hypertension these studies. However, we have previously demonstrated that cortisol-induced hypertension is not simply a result of sodium and fluid retention as the blood pressure raising effects of cortisol are not blocked by co-administration of the mineralocorticoid antagonist spironolactone. 2 It seems unlikely that the fall in haematocrit was the primary stimulus for increased EPO production as significant increases in EPO concentrations were observed within 24 h of treatment whereas haematocrit was not observed to fall significantly for 3 days. Furthermore, there was no correlation between the change in haematocrit and the change in EPO concentrations in Study 2. There is limited evidence that glucocorticoids may regulate the EPO gene expression. In foetal sheep bilateral adrenalectomy causes a significant increase in renal EPO messenger ribonucleic acid (RNA) levels and this change is reversed by cortisol infusion. 9 Dexamethasone treatment of pregnant ewes in mid-term gestation decreased foetal but not adult renal EPO messenger RNA (mRNA) levels. 9 Thus there is evidence that glucocorticoids may have a negative regulatory effect on EPO gene expression in foetal sheep. No similar data on the effect of glucocorticoids on EPO production are available in humans. In this study, the change in EPO concentration is opposite to that predicted by the effects of glucocorticoids on EPO gene expression in foetal sheep suggesting that alteration in gene expression is an unlikely explanation for the rise in EPO concentration observed in this study. It is possible that the rise in EPO concentration occurs as a consequence of some physiological effect of cortisol suggest as alteration in renal vascular resistance. In patients with essential hypertension an inverse correlation between renal plasma flow and EPO concentration has been reported. 6 Further investigation will be required to determine whether cortisol-induced changes in renal blood flow contribute to the rise in plasma EPO concentrations.
In subjects treated with 200 mg cortisol per day, a significant and positive correlation between serum EPO concentrations and blood pressure was observed. Similar correlations have been reported in subjects with essential hypertension in whom EPO Journal of Human Hypertension is correlated with ambulatory SBP and DBP. 6 These observations do not prove a causative relationship between EPO and hypertension. However, it is known that EPO has vascular effects which may contribute to hypertension. Recombinant human EPO (rHuEPO) causes contraction of isolated resistance vessels of the renal and mesenteric vascular beds. 7 These effects are endothelium independent and are not abolished by calcium antagonists or angiotensin II (AII) receptor antagonists. In cultured human coronary artery cells EPO causes dosedependent inhibition of basal and acetylcholine stimulated nitric oxide (NO) production and eNOS protein expression suggesting that EPO may also alter vascular reactivity by endothelium dependent mechanisms. 10 In partially nephrectomised rats, EPO causes an increase in blood pressure which is independent of the rise in haematocrit. 8 In these rats the hypotensive effects to NO donors such as sodium nitroprusside is impaired suggesting relative NO resistance. 8 These observations are relevant in the setting of cortisol-induced hypertension as we have demonstrated that cortisol treatment results in suppression of plasma nitrate/nitrite concentrations which occurs over the same time course as the rise in blood pressure.
Acute increases in preproendothelin 1 (prepro ET-1) and endothelin 1 (ET-1) concentrations have been observed in humans after a single intravenous dose of rHuEPO.
11 Increased prepro ET-1 mRNA has also been observed in cultured bovine aortic endothelial cells and human umbilical vein endothelial cells stimulated with pharmacological doses of rHuEPO. 12 We have been unable to demonstrate any change in urinary ET-1 concentrations in cortisol treated subjects. 13 However, the described effects of EPO on vascular reactivity may be important in cortisol treated subjects in mediating a shift of vascular reactivity away from dilator substance such as NO and in favour of constrictor substances such as endothelin. Although a rise in calculated total peripheral vascular resistance is not observed in cortisol-induced hypertension, significant increases in regional vascular resistance have been observed in cortisol treated human subjects and in adrenocorticotropin hormone (ACTH) treated rats and sheep. 1 These changes in regional resistance may be important in the pathogenesis of glucocorticoidinduced hypertension.
The changes described in all of these studies are in the context of short-term cortisol treatment. There are currently no data on the role of EPO in chronic conditions of glucocorticoid excess such as Cushing's disease. However, as we have previously described 1 the onset of cortisol-induced hypertension is acute and occurs within 24 h and is sustained for the duration of cortisol treatment. This observation is consistent with the notion that the acute effects described in studies such as these are also relevant to hypertension in more chronic conditions of glucocorticoid excess. However, in chronic glucocorticoid excess other changes such as structural changes in vascular smooth muscle and the onset of obesity may be important factors in maintaining hypertension.
In summary these data show that cortisol-induced hypertension is accompanied by a rise in serum EPO concentrations and that there is a significant positive relationship between the rise in blood pressure and the rise in serum EPO concentrations. The mechanism by which cortisol increases plasma EPO concentration remains unclear and similarly it is not clear whether EPO plays a pathogenic role in cortisol-induced hypertension. These are areas which require further investigation.
